271results about "Radioactive preparation forms" patented technology

A method of generating an emulsion for treating a patient. The method includes generating a water-based solution carrying an agent which turns into a hydrogel by addition of calcium ions. Radium radionuclides are added to the water-based solution in a concentration sufficient for radiotherapy. After adding the radium to the water-based solution, the water-based solution is mixed with an emulsifier and an oil.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and / or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.

Systems and methods are disclosed for determining the spatial distributions of radionuclides in tissue samples via mass spectrometry imaging. After administration of a radiopharmaceutical that contains a radionuclide, a mass spectrometry imaging system, such as an imaging mass cytometer or a multiplexed ion beam imaging system, is employed to interrogate a tissue sample to obtain a dataset. The radiopharmaceutical includes, or generates via radioactive decay of the radionuclide, a metal isotope detectable by the mass spectrometry imaging system. The dataset is processed to determine a spatial distribution of the metal isotope within the tissue sample, thereby characterizing the spatial distribution of the radionuclide delivered within the tissue sample. The tissue sample may be stained with a biomarker reagent that includes an additional metal isotope attached to a biomarker ligand, enabling the spatially multiplexed and co-registered analysis. The present methods can be adapted to infer and assess localization of non-radioactive pharmaceuticals.

The present disclosure generally relates to materials, processes, generators, and / or systems, for generating radioisotope. The present disclosure also generally relates to ceramic materials comprising radioisotope suitable for use in a radioisotope generator. The present disclosure also generally relates to processes, generators and / or systems, for producing and capturing radioisotope. The present disclosure also generally relates to the preparation of radioisotope solutions for use in radiopharmacy and / or other clinical applications.

The application provides a radionuclide nanohydrogel microneedle and a preparation method and application thereof, and belongs to the field of nanobiomedicine. 32 P-labeled calcium phosphate, which is formed by a biomimetic reaction of Ag2S@Ca 32 P nanoparticles, and a base layer which is a base matrix and comprises hyaluronic acid 32 P nanohydrogel microneedle can release Ag2S nanoparticles in response to a weakly acidic tumor environment, and under the irradiation of near-infrared light, the photothermal conversion efficiency can effectively kill bacteria, effectively improve the tumor hypoxic environment, enhance the treatment effect of radionuclides, play an antibacterial and wound healing promoting role in melanoma defect repair, and maximize the inhibition of tumor growth and tumor recurrence.

Liposomes encapsulating a radioisotope can be used in the treatment of cancers including, but not limited to, leptomeningeal metastases. In an embodiment, liposome encapsulating a radioisotope comprising (186Re) obisbemeda can be administered to a patient through an Ommaya reservoir. The therapies can include imaging the liposome encapsulating a radioisotopе concomitant or subsequent to administration. Longitudinal analysis of the presence of tumor cells and biomarkers can be used to inform treatment strategy.

The invention discloses a radioactive medical isotope Ra-223 stably-labeled rare earth nano diagnosis and treatment preparation as well as a preparation method and application thereof. According to the invention, by constructing a dual protection mechanism of the shell layer and the functional biomolecular layer, the Ra-223 is effectively packaged, the recoil nuclei of the Ra-223 are reserved at the tumor part and are prevented from escaping to the surrounding environment of the tumor, the safety of the Ra-223 treatment process can be enhanced, the radioactive energy is ensured to accurately act on the focus, and the treatment effect of the Ra-223 is improved. Meanwhile, the damage risk to healthy tissues is minimized.

The present application provides a liquid composition of Compound I, a preparation method therefor, and an application thereof, wherein same is selected from one or more among vitamin C, sodium vitamin C, and gentisic acid. By optimizing process parameters and technological process, the method of the present application can be applied to large-scale production, and the product prepared has high radiochemical purity, high activity and concentration, good product stability, high and stable yield or productivity.

The invention discloses a coated yttria-90 loaded radioactive microsphere and a preparation method and application thereof, and relates to the technical field of radioactive microsphere preparation, and the preparation method comprises the following steps: preparing a polyvinyl alcohol microsphere by using a microfluidic technology; the preparation method comprises the following steps: labeling polyvinyl alcohol microspheres with yttrium-90 radionuclide to obtain yttrium-90 loaded radiation microspheres; and coating the polylactic acid-glycolic acid copolymer on the surface of the yttria-90 loaded radioactive microsphere to obtain the coated yttria-90 loaded radioactive microsphere. The composite radioactive microspheres with uniform particle size, stable radioactivity and controllable characteristics can be obtained, and the composite radioactive microspheres are expected to be applied to transcatheter arterial radioembolism (TARE) treatment of liver cancer.

This invention discloses a lipid assembly loaded with 5-aminolevulinic acid and its preparation method. The lipid assembly is a hollow sphere with a core consisting of a hydrophilic phospholipid-chelating agent conjugate formed by chelation with a reactive phospholipid PEG reagent. The outer layer of the phospholipid-chelating agent conjugate is loaded with 5-aminolevulinic acid via hydrazone bonds, and then combined with a radionuclide as an internal light source excitation photosensitizer. The lipid assembly is loaded with 5-ALA via hydrazone bonds. Utilizing the acid-sensitive bond-breaking characteristics of hydrazone bonds and the prodrug properties of 5-ALA, combined with a radionuclide labeled on the surface of the lipid assembly as an internal light source excitation photosensitizer, this invention can overcome the limitations of external light penetration depth in traditional photodynamic therapy, achieving deep PDT treatment. Combined with chemotherapy drugs, it can minimize the toxic side effects on normal tissues during the combined use of radionuclides and photosensitizers in targeted therapy.

The application provides probiotic oral burst balls and a preparation process, and belongs to the technical field of probiotic embedding. The probiotic oral burst balls comprise core materials and wall materials. The core materials comprise probiotic raw materials, a flavoring agent, mannose, xylitol, mannose oligosaccharide, glycine, vitamin E and a solvent 1, and the solvent 1 is an oily solvent. The wall materials comprise trehalose, gelatin, cyclic dextrin and a solvent 2, and the solvent 2 is an oily solvent. The probiotic oral burst balls prepared by the preparation process have the characteristics of temperature resistance, acid resistance and storage resistance.

A method for producing a titanium molybdate material.SOLUTION: The method includes reacting a metallic molybdenum-99 (Mo-99) material in a liquid medium with a first acid to obtain a Mo composition, combining the Mo composition with a titanium source to obtain a Ti-Mo composition, and pH adjusting the Ti-Mo composition with a base to precipitate a plurality of Ti-Mo particulates.SELECTED DRAWING: Figure 1

An aqueous emulsion system substantially or completely devoid of an oil phase. The aqueous emulsion can be used as a platform to solubilize poorly water-soluble chemical compounds for use in a variety of fields, including the pharmaceutical, cosmetic, skin care, personal care, food, and industrial arenas. The aqueous emulsion can be delivered to a human or animal via a variety of modes to treat a diverse number of ailments, such as a topical composition to promote hair growth or treat skin disorders. Stable and transparent formulations of the aqueous nano-emulsions described herein can be used to treat and / or prevent hair loss, to treat warts and cold sores, or to treat varicose veins.

The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting moiety linked to a chelating moiety, and a stabilizer against radiolytic degradation of a radiolabeled complex comprising para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof. The pharmaceutical composition of the present invention is characterized by high stability of its radiolabeled complex against radiolytic degradation. The present invention also provides a method for preparing such a pharmaceutical composition, and use of para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof for the stabilization of the radiolabeled complex of such a pharmaceutical composition.

This invention relates to the fields of brachytherapy and radiosensitization, specifically providing a... 125 I-nano implantable particles, their preparation methods, and applications. 125 The 1-nanometer implanted particles have a core-shell structure, consisting of a particle core and particles adsorbed on the outer surface of the particle core. 125 I and the particles encapsulated in the nucleus and 125 The outer shell of the I-type photosensitizer is a covalent organic framework. This invention... 125 The core of the I-nanometer implanted particle is used to enhance the energy deposition of gamma rays and X-rays, generating more hydroxyl radicals; the shell containing a type I photosensitizer is used to absorb the energy of Auger electrons and internal conversion electrons and excite the photosensitizer to generate singlet oxygen, effectively improving the response to... 125 The efficiency of I decay energy utilization. 125 I-nano implanted particles, combined with internal radiation therapy and radiodynamic therapy, destroy tumor cell DNA and cell membranes, enhance tumor killing and induce immunogenic cell death, thereby activating anti-tumor immunity and inducing remote effects.

The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.

The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and / or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Some embodiments relate to imageable radioisotope microspheres. In some embodiments, the imageable microspheres are radiolabeled with an imageable radioisotope. In some embodiments, the imageable radioisotope is directly chemically coupled to the surface of the microsphere matrix. In some embodiments, the imageable microspheres can be used as surrogate particles to predict the distribution of therapeutic microspheres containing radiotherapeutic isotopes.

The invention belongs to the technical field of pharmaceutical chemistry, radiopharmaceutical chemistry and clinical nuclear medicine, and particularly relates to a rotaxane protection-based radioactive halogen labeled compound as well as a preparation method and application thereof. A rotaxane protection-based radioactive halogen labeled compound comprises: a macrocyclic compound having a cavity, the macrocyclic compound comprising one of cyclodextrin, cucurbituril, calixarene and pillararene; a radioactive halogen-labeled compound: the radioactive halogen-labeled position is located in the cavity of the macrocyclic compound; and the end-capping group is positioned at the opening end of the cavity, is connected to two ends of the radioactive halogen-labeled compound and is used for preventing the radioactive halogen-labeled compound from sliding out of the cavity. The rotaxane protection-based radioactive halogen labeled compound provided by the invention has good in-vivo stability, and solves the problem of poor in-vivo stability caused by dissociation of radioactive halogen and a tracer agent in the existing radioactive halogen labeled compound.

A radiation therapy source (20, 30, 40) for treating a tumor includes a flexible core (22) impermeable to radon and a polymeric coating (28, 48) on the flexible core. The polymer coating is impermeable to radium and allows radon to diffuse through the polymer coating. The radiation therapy source further includes an alpha-emitting radium radionuclide (26) in the polymer coating or between the flexible core and the polymer coating.

The invention discloses hydrogel microspheres capable of loading radioactive isotopes and a preparation method of the hydrogel microspheres. The microsphere is formed by copolymerizing a macrocyclic ligand structure, a hydrophilic monomer and a cross-linking agent, and a macrocyclic ligand is connected with a polymer main chain through a bridging structure containing p-aminobenzoic acid and aliphatic diamine and can efficiently and stably complex various radioactive isotopes. The microspheres have the characteristics of being close to water in density, good in suspension property, smooth in surface and rich in elasticity, and are easily and uniformly distributed in tumor peripheral blood vessels. The preparation method comprises the following two routes: firstly synthesizing the functional monomer and then copolymerizing, or firstly preparing the microspheres and then gradually grafting. The problems that existing microsphere nuclides are prone to falling off, high in density and poor in suspension property are effectively solved, and the microsphere is suitable for interventional radioactive embolism treatment.

The invention provides an LAG-3 targeted diagnosis and treatment integrated molecular imaging probe as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) carrying out ultrafiltration on an anti-human LAG-3 monoclonal antibody by using a buffer solution; adding a bifunctional chelating agent for reaction, and performing ultrafiltration purification to obtain a labeled precursor DOTA-alphaLAG-3; (2) mixing the labeled precursor DOTA-alphaLAG-3 with a buffer solution, and then adding radionuclide for reaction; and after the reaction is finished, carrying out ultrafiltration purification on the obtained reaction liquid to obtain the LAG-3 targeted diagnosis and treatment integrated molecular imaging probe. The obtained LAG-3 targeted diagnosis and treatment integrated molecular imaging probe can play a synergistic anti-tumor effect with immunotherapy.

The present invention relates to polymer radiotherapy particles, compositions and methods of production thereof, wherein the radionuclides are alpha and / or beta-emitting radionuclides. The invention also relates to the use of said particles and compositions in the treatment of cancer and their use in localized region radiation therapy, brachytherapy and transarterial radioembolism.

This invention discloses a load 32 The preparation method of the ultrathin sheet-like chitosan hydrogel applicator of P includes: (1) preparing a chitosan aqueous solution; (2) adding methacrylic anhydride to the chitosan aqueous solution to obtain methacrylated chitosan; (3) preparing a methacrylated chitosan aqueous solution; (4) adding 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylphenylacetone to the methacrylated chitosan aqueous solution to obtain a chitosan hydrogel precursor solution; (5) coating the inner wall of a polytetrafluoroethylene mold with a superhydrophilic coating; (6) adding Na2H 32 PO4 aqueous solution and chitosan hydrogel precursor solution are added to the mold, stirred and then cured by light; (7) the cured hydrogel is taken out and sealed between two layers of transparent tape. This application can prepare an ultra-thin hydrogel applicator, thereby reducing the obstruction of radiation by the hydrogel material itself and enhancing the therapeutic effect of the applicator.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.

The present invention relates to a novel compound comprising an ester group and uses thereof and, more particularly, to a novel compound that exhibits excellent visualization ability in a tumor by using the difference in activity of esterase for each organ in the body, and to uses therefor for diagnosing or treating cancer. A novel compound of chemical Formulas 1 to 8 according to the present invention exhibits selectivity according to the difference in activity of esterase for each organ due to ester residue in a structure, and thus is extremely effective in visualizing pancreatic cancer, etc.

The application belongs to the technical field of biological medicine, and particularly relates to an ultrathin radioactive patch for skin cancer treatment and a preparation method thereof. The preparation method comprises the following steps: adding a photoinitiator solution into a methyl methacrylate gelatin solution, and performing water bath heating dissolution under light shielding conditions; after the dissolution is completed, mixing the radioactive particles used for external irradiation treatment, stirring to a semi-solid state, smearing to a patch bottom film by using a smearing part, covering the patch anti-adhesion paper on the surface, irradiating and curing by using a light source, and obtaining the ultrathin radioactive patch. The patch prepared by the application can be customized according to the size and shape of a lesion site, a corresponding bottom film is cut out and attached to the lesion site, and smearing is directly performed. Compared with a common radioactive hydrogel, the preparation method is simpler, the preparation time is shorter, and the efficiency is higher.

The invention relates to a composition. The present invention relates to a solid carrier, an engineered phenylalanine ammonia lyase or a fragment thereof immobilized on the surface of the solid carrier, and a protective layer for protecting the engineered phenylalanine ammonia lyase or the fragment thereof by embedding the engineered phenylalanine ammonia lyase or the fragment thereof, and a functional component fixed on the surface of the protective layer, in which the functional component fixed on the surface of the protective layer is a polymer comprising repeating units, in which each repeating unit comprises at least one amino group and / or at least one mercapto group. The invention also relates to a method for producing said composition and to the use thereof.